Navigation Links
NuMedii, Inc. Announces New Partnership To Discover And Advance New Treatments For Idiopathic Pulmonary Fibrosis
Date:4/11/2017

MENLO PARK, Calif., April 11, 2017 /PRNewswire/ -- NuMedii, Inc. today announced the formation of a strategic partnership with Three Lakes Partners, LLC, to discover and advance new treatments for idiopathic pulmonary fibrosis (IPF) based on NuMedii's Big Data intelligence technology. Idiopathic pulmonary fibrosis is a rare chronic progressive and usually fatal interstitial lung disease for which the origin is unknown. Three Lakes Partners is an investment and philanthropic entity whose mission is to accelerate the development of promising technologies for IPF.

NuMedii's Big Data technology employs deep learnings of human biology consisting of hundreds of millions of unstructured public, molecular, pharmacological and clinical data points that the company has curated and harmonized. The company couples these data with proprietary machine learning and network-based algorithms to discover and advance precise, effective new drug candidates, as well as biomarkers predictive of efficacy for subsets of patients, in a broad spectrum of therapeutic areas including rare diseases like IPF.

"We look forward to working with Three Lakes Partners to identify potential new therapies for IPF, a serious and often fatal lung disease for which there is no effective treatment," said Gini Deshpande, Ph.D., chief executive officer, NuMedii, Inc. "This unique partnership between an AI drug discovery company and a patient-centric organization further builds on our work in inflammation and showcases our progress, particularly our development capabilities in rare disease."  

NuMedii's Big Data technology is being initially utilized to find new indications for safe, existing drugs for unmet medical needs in inflammation and oncology with expansion potential to multiple other therapeutic areas. NuMedii has previously entered into two inflammatory disease discovery collaborations with Aptalis and Allergan in the areas of ulcerative colitis and psoriasis, respectively.

Financial terms of the agreement were not disclosed.

About NuMedii, Inc.
NuMedii, Inc., discovers effective new drugs by translating its predictive data intelligence technology into therapies with a higher probability of therapeutic success. The company's exclusive Big Data technology, originally developed at Stanford University, utilizes large amounts of scientific data together with proprietary biological network-based algorithms to discover drug-disease connections and biomarkers that are predictive of efficacy. NuMedii translates these predictions into novel de-risked drug candidates and partners with pharmaceutical companies for development and commercialization. Headquartered in Menlo Park, California, NuMedii's investors include Claremont Creek Ventures and Lightspeed Venture Partners. For more information, please visit www.numedii.com.

About Three Lakes Partners
Three Lakes Partners, LLC, is an investment and philanthropic vehicle whose mission is to accelerate the development of promising technologies for Idiopathic Pulmonary Fibrosis (IPF). Three Lakes Partners provides not only financial support, but also operational leverage via partnership with a greater network of IPF resources worldwide. Visit www.threelakespartners.org for more information.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/numedii-inc-announces-new-partnership-to-discover-and-advance-new-treatments-for-idiopathic-pulmonary-fibrosis-300437651.html


'/>"/>
SOURCE NuMedii, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. NuMedii, Inc. Announces New Indications Discovery Collaboration With Astellas
2. NuMedii, Inc. Announces Research Collaboration with Allergan To Explore New Treatments For Psoriasis
3. CryoLife Announces Release Date and Teleconference Call Details for 2017 First Quarter Financial Results
4. 1CellBiO Inc announces Collaboration Agreement with UCB
5. Valeant Pharmaceuticals Announces 2017 Annual Meeting Of Shareholders Webcast And Q1 2017 Financial Results Conference Call
6. NuVasive Announces Conference Call And Webcast Of First Quarter 2017 Results
7. PTC Therapeutics Announces Departure of Chief Financial Officer, Shane Kovacs
8. Egalet Corporation Announces Changes to Board of Directors
9. Axovant Sciences Announces Appointment of Dr. David Hung as Chief Executive Officer and Expansion of Board of Directors
10. Non-Opioid Drug Development Firm, CerSci Therapeutics, Announces Appointment of Pharma Leaders Pat Confalone and Perry Molinoff to the Board of Directors
11. Endo International plc Announces Proposed Private Offering of Senior Secured Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... Hill-Rom Holdings, Inc. (NYSE: HRC), will host its fiscal ... Friday, November 3, 2017, beginning at 7:00 a.m. (CDT) ... a.m. (CDT) / 9:30 a.m. (EDT). In ... guidance for 2018, Hill-Rom executives will also highlight the ... long-range financial outlook through 2020. ...
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., a ... design, and immune-engineering today announced the launch of ... development of personalized therapeutic cancer vaccines. EpiVax has ... exclusive access to enabling technologies to the new ... will lead EpiVax Oncology as Chief Executive Officer. ...
(Date:9/19/2017)... , Sept. 19, 2017   ZirMed Inc ., ... analytics, today announced that it has been ranked #1 by ... Black Book™ Rankings 2017 User Survey. ZirMed was recognized ... for large hospitals and medical centers over 200 beds and ... Book,s healthcare technology user survey history. ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance (FHC), an ... showcase a range of technology and learning solutions at the 68th Annual American ... to be held October 14–18, 2017 at the Mandalay Bay Resort in Las ...
(Date:10/12/2017)... WAUSAU, Wis. (PRWEB) , ... October 12, 2017 ... ... formulated standard products to meet the demand of today’s consumer and regulatory authorities ... team of probiotic experts and tested to meet the highest standard. , ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... AccentCare, a leader in post-acute health care, have expanded their existing home health ... Home Health. , AccentCare has been operating a joint venture home health company ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... HMP ... the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare ... City on October 11, 2017. , The annual award competition recognizes editorial and design ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... been named one of Michigan’s 2017 Best and Brightest in Wellness® by Best ... in Wellness® awards program on Friday, Oct. 20 from 7:30 a.m. to 2 ...
Breaking Medicine News(10 mins):